Table 1 The demographic and clinical characteristics of the subjects

Age (mean ± SD) (year)

28.2 ± 14.2

27.8 ± 10.6

27.5 ± 11.6

Female [n (%)]

31 (67.4%)

175 (57.2%)

206 (58.5%)

Years of education (mean ± SD) (year)

12.0 ± 3.5

12.5 ± 3.3

12.4 ± 3.3

 Married [n (%)]

14 (30.4%)

95 (31.0%)

109 (31.0%)

 Single [n (%)]

29 (63.0%)

199 (65.0%)

228 (64.8%)

 Divorced [n (%)]

3 (6.5%)

11 (3.6%)

14 (4.0%)

 Widowed [n (%)]

0 (0.0%)

1 (0.3%)

1 (0.3%)

Psychotic features [n (%)]

9 (19.6%)

66 (21.6%)

75 (21.3%)

Atypical features

N = 44

N = 297

N = 341

 Increased appetite [n (%)]

6 (13.0%)

68 (22.9%)

74 (21.7%)

 Weight gain [n (%)]

4 (8.7%)

55 (18.5%)

59 (17.3%)

 Hypersomnia [n (%)]

14 (30.4%)

81 (27.3%)

95 (27.0%)

Comorbidity of thyroid diseases^a

5 (10.9%)

14 (4.6%)

19 (5.4%)^b

Substance abuse [n (%)]

2 (4.3%)

22 (7.2%)

24 (6.8%)

HAMD-17 total scores (mean ± SD)

19.4 ± 7.6

18.7 ± 9.5

18.7 ± 9.2

YMRS total scores (mean ± SD)

8.3 ± 8.0

11.8 ± 10.5^*

11.3 ± 10.4

BMI (mean ± SD)

21.4 ± 3.5

21.8 ± 3.6

21.7 ± 3.5

 remission

3 (6.5%)

28 (9.2%)

31 (8.8%)

 depressive

27 (58.7%)

144 (47.1%)

171 (48.6%)

 (hypo)manic

1 (2.2%)

29 (9.5%)

30 (8.5%)

 mixed

15 (32.6%)

105 (34.3%)

120 (34.1%)

Duration of illness (mean ± SD) (year)

5.1 ± 5.7

4.9 ± 6.0

4.8 ± 5.9

Psychopharmaceutical treatment [n (%)]

15 (32.6%)

105 (34.3%)

120 (34.1%)

 Lithium [n (%)]

2 (4.3%)

19 (6.2%)

21 (6.0%)

 Anticonvulsants [n (%)]

8 (17.4%)

46 (15.1%)

54 (15.3%)^b

 Antipsychotics [n (%)]

10 (21.7%)

80 (26.1%)

90 (25.5%) ^c

 Antidepressants [n (%)]

9 (19.6%)

38 (12.4%)

47 (13.4%)^d